Spinal stimulation offers new hope for autonomic recovery after injury

NCT ID NCT05369520

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive spinal cord stimulation device can improve autonomic functions like blood pressure, bladder, bowel, and sexual control in people with chronic spinal cord injury. Thirty participants will receive targeted stimulation over several weeks. The goal is to see if this approach can safely ease common complications and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Resident of British Columbia, Canada with active provincial medical services plan. 2. Male or female, 19-60 years of age. 3. Chronic traumatic SCI (non-progressive, with complete motor paralysis) at or above the T6 spinal segment. 4. \>1-year post injury, at least 6 months from any spinal surgery. 5. American Spinal Injury Association Impairment Scale (AIS) A, B. 6. Stable management of spinal cord related clinical issues (i.e., spasticity management). 7. Experience bladder, or bowel, or sexual dysfunction. 8. No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing. 9. For women of childbearing potential, not intending to become pregnant, currently pregnant, or lactating. The following conditions apply: 1. A confirmed negative pregnancy test prior to the baseline visit. During the trial, all women of childbearing potential will undergo urine pregnancy tests at their monthly clinic visits as outlined in the schedule of events. 2. Use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment. 3. If using combined hormonal contraception, a stable regimen during the period of the trial and for at least 28 days after completion of treatment. 10. For sexually active males with female partners of childbearing potential, use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment. 11. Must provide informed consent. 12. Willing and able to comply with all clinic visits and study-related procedures. 13. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator). Exclusion Criteria: 1. Ventilator dependent. 2. Signs of lower motor neuron damage (i.e. concomitant conus medullaris/cauda equina injury). 3. Severe anemia or hypovolemia as measured by hematocrit via blood test in the last six months. 4. History of cardiovascular, respiratory, bladder, or renal disease unrelated to SCI or presence of hydronephrosis or presence of obstructive renal stones. 5. History of seizures/epilepsy or recurring headaches. 6. Clinically significant, unmanaged, depression (to be screened) or ongoing drug abuse. 7. Intrathecal baclofen pump. 8. Oral baclofen dose greater than 60mg. 9. Individuals that have received intradetrusor or intrasphincter onabotulinumtoxinA injections within 6 months of baseline. 10. Any implanted metal (other than dental implants) in the skull or presence of pacemakers, stimulators, or medication pumps in the trunk. 11. Past electrode implantation surgery. 12. Member of the investigational team or his/her immediate family. 13. Presence of severe acute medical issue and use of any specific medication or treatment that, in the investigator's judgement, would adversely affect the participant's participation in the study. 14. Known allergies or sensitivities to both blue dye and beetroot powder. 15. Known or suspected gastrointestinal obstruction. 16. Persons with active inflammatory bowel disease or a history of bowel perforation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic dysfunction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Blusson Spinal Cord Centre

    RECRUITING

    Vancouver, British Columbia, V5Z 1M9, Canada

  • St Paul's Hospital

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.